Eledon Q2 FY26 net loss widens to $31.6 million
Reuters2026/08/13 20:08- Eledon Pharmaceuticals posted a wider Q2 2026 net loss of USD 31.6 million, or USD 0.27 per share, versus USD 11.2 million.
- R&D expense fell to USD 18.2 million from USD 20.3 million, while G&A edged up to USD 4.6 million from USD 4.5 million.
- Cash, cash equivalents and short-term investments slid to USD 88.8 million at June 30 from USD 133.3 million at Dec. 31.
- Net loss included a USD 9.6 million non-cash warrant fair-value loss versus a USD 12.3 million non-cash gain a year earlier.
- David-Alexandre C. Gros said a successful FDA end-of-Phase 2 meeting keeps a global Phase 3 kidney transplant trial on track for late 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
UBS lowers Ciena target price to $394
EUR/USD Price Forecast: Holds key 100-day SMA at start of the US CPI week
Malaysia Govt Spending Plan Could Help 99 Speed Mart Retail -- Market Talk
Paying the price for supporting the yen? Japan's foreign reserves fell by $87.8 billions in August, possibly due to selling US Treasuries for funding.
Japanese authorities may have used part of their foreign exchange reserves, including foreign securities such as U.S. Treasury bonds, over the past month to fund record-sized foreign exchange intervention operations.
Crypto prices
More
